Board of Directors

James R. McNab, Jr.
Chairman of the Board, Curis
Chief Executive Officer and Chairman of eNOS Pharmaceuticals, Inc.; Executive Chairman of Argolyn Bioscience, Inc.

Susan B. Bayh
Director, Dendreon Corporation, Dyax Corporation, Emmis Communications, Nastech Pharmaceutical Corporation and Wellpoint, Inc.
Formerly Commissioner of the International Commission between the United States and Cananda; Formerly attorney in the Pharmaceutical Division of Eli Lilly and Company

Stephen K. Carter, M.D.
Director, Alfacell Corporation, Callisto Pharmaceuticals, Inc. Cytogen Corporation, Emisphere Technologies, Inc., Tapestry Phamaceuticals, Inc., and Vion Pharmaceuticals, Inc.
Former SVP of Worldwide Clinical Research & Development for Bristol Myers Squibb Pharmaceuticals

Joseph M. Davie, Ph.D., M.D.
Director, CV Therapeutics, Inc. and Targeted Genetics, Inc.
Formerly Sr. Vice President of Research at Biogen, Inc. (now Biogen Idec); Elected to Institute of Medicine

Martyn D. Greenacre
Chairman of Beijing Med-Pharm Corporation and Life Mist LLC
Director, Cephalon, Inc., Acusphere, Inc. and The Immune Response Corporation

Kenneth I. Kaitin, Ph.D.
Director of the Tufts Center for the Study of Drug Development
Associate Professor of Medicine at Tufts University School of Medicine; Serves on Faculty of European Center for Pharmaceutical Medicine at the University of Basel

Daniel R. Passeri
President and Chief Executive Officer, Curis, Inc.

James R. Tobin
President and Chief Executive Officer, Boston Scientific Corporation
Director, Applera Corporation and Boston Scientific Corporation